Thierry Le Chevalier - JoVE Visualize

Showing results (61-70 of 81) with videos related to

Pageof 9

Sort By:

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapyJohan Vansteenkiste, Primo N Lara, Thierry Le Chevalier, et al.

Translational Lung Cancer Research|March 15, 2021

Prognostic and predictive effect of <i>KRAS</i> gene copy number and mutation status in early stage non-small cell lung cancer patientsAndrea S Fung, Maryam Karimi, Stefan Michiels, et al.

Lancet (London, England)|July 31, 2002

Malignant effusions and immunogenic tumour-derived exosomesFabrice Andre, Noel E C Schartz, Mojgan Movassagh, et al.

Translational Lung Cancer Research|July 28, 2018

Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancerFederico Rotolo, Chang-Qi Zhu, Elisabeth Brambilla, et al.

Lung Cancer (Amsterdam, Netherlands)|February 16, 2013

PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outsKen A Olaussen, Julien Adam, Elsa Vanhecke, et al.

Clinical Lung Cancer|July 12, 2023

Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio DataPrashanth Ashok Kumar, Maryam Karimi, Alina Basnet, et al.

Lung Cancer (Amsterdam, Netherlands)|August 21, 2013

10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL)Wilfried Ernst Erich Eberhardt, Thomas Christoph Gauler, Cecile Lepechoux, et al.

The New England Journal of Medicine|September 8, 2006

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapyKen A Olaussen, Ariane Dunant, Pierre Fouret, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2017

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant ChemotherapyFrances A Shepherd, Benjamin Lacas, Gwénaël Le Teuff, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 23, 2016

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled AnalysisXiaoli Ma, Gwénaël Le Teuff, Benjamin Lacas, et al.

Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:

Pageof 9

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapyJohan Vansteenkiste, Primo N Lara, Thierry Le Chevalier, et al.

Translational Lung Cancer Research|March 15, 2021

Prognostic and predictive effect of <i>KRAS</i> gene copy number and mutation status in early stage non-small cell lung cancer patientsAndrea S Fung, Maryam Karimi, Stefan Michiels, et al.

Lancet (London, England)|July 31, 2002

Malignant effusions and immunogenic tumour-derived exosomesFabrice Andre, Noel E C Schartz, Mojgan Movassagh, et al.

Translational Lung Cancer Research|July 28, 2018

Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancerFederico Rotolo, Chang-Qi Zhu, Elisabeth Brambilla, et al.

Lung Cancer (Amsterdam, Netherlands)|February 16, 2013

PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outsKen A Olaussen, Julien Adam, Elsa Vanhecke, et al.

Clinical Lung Cancer|July 12, 2023

Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio DataPrashanth Ashok Kumar, Maryam Karimi, Alina Basnet, et al.

Lung Cancer (Amsterdam, Netherlands)|August 21, 2013

10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL)Wilfried Ernst Erich Eberhardt, Thomas Christoph Gauler, Cecile Lepechoux, et al.

The New England Journal of Medicine|September 8, 2006

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapyKen A Olaussen, Ariane Dunant, Pierre Fouret, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2017

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant ChemotherapyFrances A Shepherd, Benjamin Lacas, Gwénaël Le Teuff, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 23, 2016

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled AnalysisXiaoli Ma, Gwénaël Le Teuff, Benjamin Lacas, et al.

Pageof 9